International Journal of Clinical Pharmacy

, Volume 35, Issue 1, pp 79–86

Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial

Authors

  • Aline Oliveira Magalhães Mourão
    • Post-Graduate Program in Pharmaceutical Sciences, School of PharmacyFederal University of Ouro Preto
  • Wandiclécia Rodrigues Ferreira
    • Department of Pharmacy, School of PharmacyFederal University of Ouro Preto
  • Maria Auxiliadora Parreiras Martins
    • Department of Pharmaceutical Products, School of PharmacyFederal University of Minas Gerais
  • Adriano Max Moreira Reis
    • Department of Pharmaceutical Products, School of PharmacyFederal University of Minas Gerais
  • Maria Ruth Gaede Carrillo
    • Department of Clinical Analysis, School of PharmacyFederal University of Ouro Preto
  • Andrea Grabe Guimarães
    • Department of Pharmacy, School of PharmacyFederal University of Ouro Preto
    • Department of Pharmacy, School of PharmacyFederal University of Ouro Preto
Research Article

DOI: 10.1007/s11096-012-9710-7

Cite this article as:
Mourão, A.O.M., Ferreira, W.R., Martins, M.A.P. et al. Int J Clin Pharm (2013) 35: 79. doi:10.1007/s11096-012-9710-7

Abstract

Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (−0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.

Keywords

BrazilDiabetes mellitusDiabetes type 2PharmacistsPharmaceutical careRandomised controlled trial

Copyright information

© Springer Science+Business Media Dordrecht 2012